AGER Antibody

What is AGER and why is it important in research applications?

AGER, also known as RAGE (Receptor for Advanced Glycation End products), is a multi-ligand member of the immunoglobulin superfamily of cell surface molecules. It functions as a pattern recognition receptor with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein (HMGB1), amyloid beta oligomers, nucleic acids, phospholipids, and glycosaminoglycans . AGER is critically important in research because it transduces ligand binding into pro-inflammatory responses and plays central roles in diabetes, vascular complications, neurodegenerative disorders, and cancer progression . It is associated with sustained NF-kappaB activation in diabetic microenvironments and has a central role in sensory neuronal dysfunction .

What are the key domains of AGER that antibodies typically target?

Based on the search results, AGER antibodies typically target three distinct regions:

• N-terminal domain (extracellular): Antibodies targeting amino acids 24-52 of the human AGER sequence

• Middle region: Antibodies recognizing sequences in the middle portion of AGER

• C-terminal domain (intracellular): Antibodies recognizing amino acids 348-378

Each domain-specific antibody provides unique insights into different aspects of AGER biology, with N-terminal antibodies being useful for studying ligand interactions and C-terminal antibodies for intracellular signaling pathways.

How can I determine the most appropriate AGER antibody for my experimental model?

When selecting an AGER antibody, researchers should consider:

• Species reactivity: Verify compatibility with your experimental model (human, mouse, rat)

  • Some antibodies show cross-reactivity across multiple species

  • Others may have species-specific recognition patterns

• Application compatibility: Confirm validation for your specific application

  • Western blot: Most AGER antibodies work at dilutions of 1:1000

  • IHC-P: Optimal dilutions typically range from 1:10-1:50

  • ELISA and flow cytometry: Select antibodies specifically validated for these applications

• Target epitope: Consider which domain of AGER is most relevant to your research question

  • For ligand binding studies, N-terminal antibodies may be preferred

  • For signaling studies, C-terminal antibodies may be more appropriate

What are the optimal conditions for Western blot analysis using AGER antibodies?

Based on the provided search results, researchers should consider the following protocol elements:

When interpreting results, researchers should be aware that some antibodies may detect nonspecific bands (indicated with asterisks in some publications) . Using antibodies targeting different AGER domains can help confirm specificity of detection.

How can I optimize immunohistochemistry protocols for AGER detection in tissue samples?

For successful immunohistochemical detection of AGER:

• Sample preparation options:

  • Formalin-fixed paraffin-embedded (FFPE) tissues have been successfully used with appropriate antigen retrieval

  • Fresh-frozen sections may preserve epitopes that are sensitive to fixation

• Protocol considerations:

  • Antibody dilutions typically range from 1:10 to 1:50 for IHC-P applications

  • DAB (3,3'-diaminobenzidine) staining has been demonstrated to work effectively

  • For comparative studies, consistent protocols should be maintained across all samples

• Interpretation guidance:

  • AGER expression patterns differ between normal and pathological tissues (e.g., normal skin versus SCC)

  • Expression levels can be compared between different patient groups (e.g., immunocompetent patients versus organ transplant recipients)

  • Both in situ and invasive lesions should be examined for comprehensive analysis

What functional assays can be performed using AGER antibodies?

AGER antibodies can be employed in various functional assays beyond simple detection:

• RAGE blocking experiments:

  • Pre-incubation with blocking anti-RAGE antibody (80μg/ml) can reduce cellular proliferation induced by S100A8/A9 stimulation

  • This approach allows for investigation of RAGE-dependent cellular responses

• Cell-matrix adhesion assays:

  • AGER antibodies can confirm expression levels in adhesion studies

  • RAGE has been shown to enhance adhesion to various ECM proteins including collagen I, fibronectin, and laminin

  • Time-dependent effects (15 minutes versus 45 minutes) can be quantitatively assessed

• Cell aggregation assays:

  • RAGE facilitates cell aggregation through homophilic interactions

  • These can be visualized and quantified using phase contrast microscopy

  • Mixed cell aggregation assays with labeled cells can further confirm specificity

How can I validate the specificity of AGER antibody signals in my experimental system?

Comprehensive validation strategies include:

• Multiple antibody approach:

  • Use antibodies recognizing different domains of RAGE (N-terminal, middle, and C-terminal)

  • Compare detection patterns across these antibodies, as demonstrated in rat lung lysate and R3/1 cells

• Genetic controls:

  • Comparison with RAGE-overexpressing cells versus control cells (e.g., preB/FL-RAGE versus preB/pCAGS)

  • RAGE knockdown samples using shRNA technology versus control shRNA

  • These genetic approaches provide critical positive and negative controls

• Peptide competition:

  • Pre-incubation of antibody with immunizing peptide should abolish specific signals

  • Particularly useful for polyclonal antibodies like those described in the search results

• Cross-species validation:

  • If an antibody claims reactivity across species, testing in multiple species can confirm specificity

  • Note that some antibodies target sequences that differ between human and rodent RAGE by two amino acids

What are the critical considerations when comparing AGER expression across different disease models?

Researchers should consider:

• Standardization requirements:

  • Consistent protein loading (40 μg per lane for Western blots)

  • Identical antibody concentrations and incubation conditions across all samples

  • Same detection methods and exposure times for comparative analysis

• Context-specific expression patterns:

  • RAGE and its binding partners (e.g., S100A8/A9) show differential expression in:

    • Normal versus pathological tissues

    • Early versus advanced disease stages (e.g., in situ versus invasive SCC)

    • Different patient populations (immunocompetent versus immunosuppressed)

• Functional correlations:

  • Combine expression analysis with functional readouts (e.g., proliferation assessed by BrdU incorporation)

  • Compare antibody blocking with genetic approaches (knockdown) to validate biological significance

  • Consider additional receptors that might compensate for RAGE (e.g., TLR4)

How can I troubleshoot weak or inconsistent AGER antibody signals?

When facing detection challenges:

• For weak Western blot signals:

  • Increase protein loading (up to 40-50 μg per lane)

  • Optimize primary antibody concentration and incubation time

  • Consider enhanced chemiluminescence detection systems

  • Verify sample preparation maintains protein integrity

  • Ensure antibody storage conditions are optimal (-20°C for long-term storage)

• For inconsistent IHC staining:

  • Optimize antigen retrieval method for FFPE tissues

  • Test a range of antibody dilutions (1:10 to 1:50)

  • Increase primary antibody incubation time

  • Use amplification systems for enhanced sensitivity

  • Verify positive control tissues show expected staining patterns

• For functional blocking experiments:

  • Pre-incubation time (1 hour) and antibody concentration (80 μg/ml) are critical parameters

  • Include appropriate positive controls (RAGE-dependent cellular responses)

  • Consider that high antibody concentrations may cause non-specific effects

How can AGER antibodies be used to study receptor-mediated signaling pathways?

AGER antibodies provide valuable tools for investigating signaling mechanisms:

• Receptor-ligand interactions:

  • RAGE interactions with S100 proteins can be studied using blocking antibodies

  • Functional consequences of these interactions can be measured using proliferation assays

  • Comparison with other receptors (e.g., TLR4) can identify specific versus redundant signaling pathways

• Downstream signaling analysis:

  • Following confirmation of RAGE expression by antibody detection, researchers can investigate:

    • NF-κB pathway activation, known to be sustained in RAGE signaling

    • Inflammatory cytokine production (e.g., IL-6)

    • Cellular phenotypic changes (proliferation, migration, adhesion)

• Therapeutic targeting assessment:

  • RAGE blocking strategies can be evaluated using antibodies before moving to more complex models

  • Dose-dependent and time-dependent effects can be systematically analyzed

What are the considerations for multiplexed detection of AGER and its binding partners?

For comprehensive analysis of RAGE biology:

How do polyclonal and monoclonal AGER antibodies compare in research applications?

The search results primarily describe polyclonal antibodies , but researchers should consider these differences:

What are the critical quality control parameters for validating AGER antibodies?

Researchers should assess:

• Specificity validation:

  • Western blot showing band at expected molecular weight (42-43 kDa)

  • Absence of signal in negative control samples

  • Comparison with genetic overexpression or knockdown

• Sensitivity assessment:

  • Detection of endogenous versus overexpressed RAGE

  • Signal-to-noise ratio in relevant applications

  • Appropriate positive controls (e.g., rat lung lysate)

• Application validation:

  • Performance in multiple applications (WB, IHC, ELISA, FC)

  • Optimal working dilutions for each application

  • Reproducibility across different experimental conditions

• Storage and stability:

  • Proper storage conditions (-20°C for long-term storage)

  • Aliquoting to avoid freeze-thaw cycles

  • Verification of performance after extended storage

By systematically addressing these considerations, researchers can ensure reliable and reproducible results when working with AGER antibodies in diverse experimental contexts.